|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 18, 2015 ) Dallas, TX -- Avastin is active against all isoforms of VEGF-A, and can prevent it from interacting with its receptors on the surface of endothelial cells, which leads to the inhibition of angiogenesis, a key feature of both wAMD and DME. Therefore, in addition to its approved therapeutic role as an oncology drug, Avastin has been used off-label for many years as an IVT anti-VEGF treatment for these retinal diseases, despite the launch of Lucentis (a mAb fragment derived from the same parent murine antibody as Avastin) in 2006 for wAMD, which was also developed by Genentech.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=312779 . (This is a premium report priced at US$3495 for a single user License.)
The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years.
Scope:
• Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Avastin for the top seven countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Inquire for discount at http://www.rnrmarketresearch.com/contacts/discount?rname=312779 .
Reasons to Buy:
• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of Avastin performance.
• Obtain sales forecast for Avastin from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
Table of Contents:
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Related Reports 10
3 Disease Overview 12
3.1 Macular Degeneration Overview 12
3.1.1 Etiology and Pathophysiology 14
3.1.2 Classification 18
3.1.3 Symptoms and Diagnosis 20
3.2 Macular Edema Overview 23
3.2.1 Etiology and Pathophysiology 24
3.2.2 Classification 27
3.2.3 Symptoms and Diagnosis 28
4 Disease Management 31
4.1 Diagnosis and Treatment Overview 31
4.1.1 Macular Edema Diagnosis 31
4.1.2 Macular Degeneration Diagnosis 31
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 48
5.1 Overview 48
6 Avastin (bevacizumab) 50
6.1 Overview 50
6.2 Efficacy - Macular Degeneration 53
6.3 Efficacy - Macular Edema 54
6.4 Safety 54
6.5 SWOT Analysis 55
6.6 Forecast 55
7 Appendix 57
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
